ArticleCell death discovery2026
Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study elucidated the mechanistic role of the Suppressor of Cytokine Signaling 5 (SOCS5) in diabetic retinopathy (DR), focusing on DNA damage and cellular senescence pathways. Utilizing both in vitro (high glucose (HG)-induced human retinal microvascular endothelial cells (HRMECs)) and in vivo (streptozotocin-induced DR mouse models) approaches, we demonstrated that SOCS5 was significantly upregulated in DR. SOCS5 knockdown mitigated retinal tissue damage, vascular leakage, and apoptosis in DR mice while reducing DNA damage and cellular senescence in HG-stimulated HRMECs. Mechanistically, SOCS5 promoted DR progression by regulating the expression of Cyclin-Dependent Kinase Inhibitor 1 A (CDKN1A), a key mediator of cell cycle arrest and senescence. Furthermore, we identified POU Class 2 Homeobox 1 (POU2F1) as an upstream transcriptional activator of SOCS5, forming a novel POU2F1-SOCS5-CDKN1A axis that drove DR pathogenesis. Inhibition of POU2F1 and SOCS5 ameliorated DR-related pathology in mice, suggesting a novel therapeutic strategy. These findings reveal a previously unrecognized signaling pathway in DR and highlight SOCS5 as a promising target for intervention.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.